Silent Mutations in the HIV-1 Reverse Transcriptase Selected during Antiretroviral Therapy

抗逆转录病毒治疗期间选择的 HIV-1 逆转录酶的沉默突变

• 批准号: nhmrc : 603704
• 负责人: A/Pr Nicolas Sluis-Cremer
• 金额: $ 37.03万
• 依托单位: Macfarlane Burnet Institute for Medical Research and Public Health
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/silent-mutations-hiv-antiretroviral-therapy/82910
• 关键词: Silent; Mutations; HIV; Reverse; Transcriptase

This project seeks to determine the role of silent mutations in the HIV reverse transcriptase that are selected during drug therapy in HIV infected individuals on HIV fitness, reverse transcriptase function and the emergence of drug resistance. This study will increase our understanding of the mechanisms by which the virus evades the effects of antiretrovirals and will provide a rationale for deciding on the best drug combinations for use in patients infected with specific HIV strains (clades).

该项目旨在确定HIV逆转录酶中沉默突变的作用，这些突变是在HIV感染者的药物治疗过程中选择的，对HIV适应性，逆转录酶功能和耐药性的出现。这项研究将增加我们对病毒逃避抗逆转录病毒药物作用的机制的理解，并将为决定用于感染特定HIV毒株（分支）的患者的最佳药物组合提供依据。